Sangamo Therapeutics (SGMOQ) Total Non-Current Liabilities (2013 - 2025)

Sangamo Therapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $73.4 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities fell 5.77% year-over-year to $73.4 million in Q4 2025; TTM through Dec 2025 was $73.4 million, a 5.77% decrease from a year earlier, with the FY2025 full-year figure at $73.4 million, down 5.77% from the prior year.
• Total Non-Current Liabilities was $73.4 million for Q4 2025 at Sangamo Therapeutics, down from $81.4 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $400.4 million in Q1 2021, with the low at $68.1 million in Q2 2024.
• Average Total Non-Current Liabilities over 5 years is $180.6 million, with a median of $86.8 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2023: Total Non-Current Liabilities jumped 117.66% in 2021, then slumped 70.56% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $345.4 million in 2021, then dropped by 22.88% to $266.3 million in 2022, then slumped by 69.5% to $81.2 million in 2023, then slipped by 4.08% to $77.9 million in 2024, then declined by 5.77% to $73.4 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $73.4 million (Q4 2025), $81.4 million (Q3 2025), and $77.0 million (Q2 2025), per Business Quant data.